{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T19:12:21Z","timestamp":1791832341633,"version":"4.3.4"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T00:00:00Z","timestamp":1728604800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To investigate the therapeutic effect of Vericiguat combined with \u201cnew quadruple\u201d drugs on patients with heart failure (HF).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>From December 1, 2022 to February 1, 2024, 103 patients with heart failure were consecutively enrolled from the cardiology clinic or ward of the First Affiliated Hospital of Nanjing Medical University. Before enrollment, the patients\u2019 left ventricular ejection fraction (LVEF), left ventricular end diastolic diameter (LVEDD), N-terminal pro-B-type natriuretic peptide (NT-proBNP), liver and kidney function electrolytes, and Minnesota Living with Heart Failure Questionnaire (MLHFQ) and other indicators were measured. Patients diagnosed with reduced ejection fraction (HFrEF) and with heart failure with mildly reduced ejection fraction (HFmrEF) were treated with Vericiguat combined with \u201cARNI, BB, MRA, SGLT2i\u201d therapy. Patients diagnosed with preserved ejection fraction (HFpEF) were treated with Vericiguat combined with \u201cARNI, BB, SGLT2i\u201d therapy. The above indicators were rechecked after 1 month of treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>For all patients, comparison after treatment: LVEF (38.1\u2009\u00b1\u20098.5% vs. 43.1\u2009\u00b1\u20098.5%, <jats:italic>P<\/jats:italic>\u2009&amp;lt;\u20090.01), LVEDD (60.5\u2009\u00b1\u20098.1 vs. 58.2\u2009\u00b1\u20097.3\u2005mm, <jats:italic>P<\/jats:italic>\u2009&amp;lt;\u20090.01), NT-proBNP (4,567.8\u2009\u00b1\u20095,163.9 vs. 1,895.6\u2009\u00b1\u20092,702.1\u2005ng\/L, <jats:italic>P<\/jats:italic>\u2009&amp;lt;\u20090.01), MLHFQ (45.72\u2009\u00b1\u200911.09 vs. 32.29\u2009\u00b1\u20099.41, <jats:italic>P<\/jats:italic>\u2009&amp;lt;\u20090.01). Further subgroup analysis showed that Vericiguat combined with \u201cARNI, BB, SGLT2i or MRA\u201d improved the LVEF and reduced NT-proBNP levels in patients with HFrEF, HFmrEF or HFpEF. and improved patients\u2019 quality of life scores. The intergroup comparison showed the therapeutic effect of the combination was equivalent in HF caused by myocardial Infarction (MI), dilated cardiomyopathy (DCM) or Valvular Heart Disease (VHD).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Vericiguat combined with the \u201cnew quadruple\u201d therapy has a significant therapeutic effect on patients with heart failure caused by MI, DCM or VHD.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2024.1476976","type":"journal-article","created":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T04:39:25Z","timestamp":1728621565000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Vericiguat combined with \u201cnew quadruple\u201d therapy enhances cardiac function and life quality in patients with heart failure: a single-center prospective study"],"prefix":"10.3389","volume":"11","author":[{"given":"Di","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghong","family":"Yong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liansheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiabao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,10,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1002\/ejhf.1236","article-title":"Advanced heart failure: a position statement of the heart failure association of the European society of cardiology","volume":"20","author":"Crespo-Leiro","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/CIR.0000000000001063","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American college of cardiology\/American heart association joint committee on clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"B3","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.jacc.2022.11.023","article-title":"Worsening heart failure: nomenclature, epidemiology, and future directions: JACC review topic of the week","volume":"81","author":"Greene","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1161\/CIR.0000000000000757","article-title":"Heart disease and stroke statistics-2020 update: a report from the American heart association","volume":"141","author":"Virani","year":"2020","journal-title":"Circulation"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: a systematic analysis for the global burden of disease study 2017","volume":"392","year":"2018","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1002\/ejhf.1629","article-title":"Prevalence of heart failure and left ventricular dysfunction in China: the China hypertension survey, 2012\u20132015","volume":"21","author":"Hao","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"B7","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3760\/cma.j.cn112148-20231101-00405","article-title":"Chinese guidelines for the diagnosis and treatment of heart failure 2024","volume":"52","year":"2024","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1001\/jama.2020.13310","article-title":"Heart failure","volume":"324","author":"Baman","year":"2020","journal-title":"J Am Med Assoc"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.3390\/biomedicines10102471","article-title":"Vericiguat in heart failure: characteristics, scientific evidence and potential clinical applications","volume":"10","author":"Vannuccini","year":"2022","journal-title":"Biomedicines"},{"key":"B11","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jchf.2017.08.013","article-title":"A multicenter, randomized, double-blind, placebo-controlled trial of the efficacy and safety of the oral soluble guanylate cyclase stimulator: the VICTORIA trial","volume":"6","author":"Armstrong","year":"2018","journal-title":"JACC Heart Fail"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.echo.2018.06.004","article-title":"Guidelines for performing a comprehensive transthoracic echocardiographic examination in adults: recommendations from the American society of echocardiography","volume":"32","author":"Mitchell","year":"2019","journal-title":"J Am Soc Echocardiogr"},{"key":"B13","doi-asserted-by":"publisher","first-page":"CD009077","DOI":"10.1002\/14651858.CD009077.pub3","article-title":"Pharmacological interventions for treating heart failure in patients with chagas cardiomyopathy","volume":"7","author":"Marti-Carvajal","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"B14","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1161\/CIRCULATIONAHA.116.027134","article-title":"Personalizing risk stratification for sudden death in dilated cardiomyopathy: the past, present, and future","volume":"136","author":"Halliday","year":"2017","journal-title":"Circulation"},{"key":"B15","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41569-020-0379-7","article-title":"Congestion in heart failure: a contemporary look at physiology, diagnosis and treatment","volume":"17","author":"Boorsma","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 Focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1007\/s40265-021-01586-y","article-title":"Drug treatment of heart failure with reduced ejection fraction: defining the role of Vericiguat","volume":"81","author":"Coats","year":"2021","journal-title":"Drugs"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1093\/eurheartj\/ehw593","article-title":"Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the soluble guanylate cyclase stimulator in heart failure patients with preserved EF (Socrates-preserved) study","volume":"38","author":"Pieske","year":"2017","journal-title":"Eur Heart J"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1001\/jama.2020.15922","article-title":"Effect of Vericiguat vs. placebo on quality of life in patients with heart failure and preserved ejection fraction: the vitality-HFpEF randomized clinical trial","volume":"324","author":"Armstrong","year":"2020","journal-title":"J Am Med Assoc"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.3390\/ijms25031574","article-title":"Current approaches to worsening heart failure: pathophysiological and molecular insights","volume":"25","author":"D'Amato","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B21","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1001\/jamacardio.2020.6455","article-title":"Clinical outcomes and response to Vericiguat according to Index heart failure event: insights from the VICTORIA trial","volume":"6","author":"Lam","year":"2021","journal-title":"JAMA Cardiol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s40265-023-01887-4","article-title":"Guideline-directed medical therapy for the treatment of heart failure with reduced ejection fraction","volume":"83","author":"Patel","year":"2023","journal-title":"Drugs"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2024.1476976\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T04:39:27Z","timestamp":1728621567000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2024.1476976\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,11]]},"references-count":22,"alternative-id":["10.3389\/fcvm.2024.1476976"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2024.1476976","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,11]]},"article-number":"1476976"}}